-
Akums Drugs Analyst Review 2027: CDMO Engine Lifts Profit 168%, Stock Runs Past Older Targets
- November 18, 2026
- Posted by: Chaitanya Auti
- Category: Market
No Comments
Akums Drugs and Pharmaceuticals grew Q2 FY27 revenue about 32% and profit about 168% as CDMO margins jumped to 15.1%. The stock now trades above earlier ICICI Securities and Citi targets. We review results, analyst views, valuation and risks for 2027.